Antipsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain
Nitric oxide synthase inhibitors have been regarded as potentially beneficial for psychiatric disorders such as depression and schizophrenia, though little is known about how nitric oxide synthases are affected by psychotropic drugs in the brain. Using reverse transcription-polymerase chain reaction...
Gespeichert in:
| Veröffentlicht in: | Neuroscience letters 2002-11, Vol.333 (3), p.217-219 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 219 |
|---|---|
| container_issue | 3 |
| container_start_page | 217 |
| container_title | Neuroscience letters |
| container_volume | 333 |
| creator | Suzuki, Eiji Nakaki, Toshio Shintani, Futoshi Kanba, Shigenobu Miyaoka, Hitoshi |
| description | Nitric oxide synthase inhibitors have been regarded as potentially beneficial for psychiatric disorders such as depression and schizophrenia, though little is known about how nitric oxide synthases are affected by psychotropic drugs in the brain. Using reverse transcription-polymerase chain reaction analysis, we investigated the effects of short- and long-term oral treatments with several psychotropics on type II nitric oxide synthase gene expression in the rat brain. With maprotiline and fluvoxamine, enzyme mRNA levels were higher after a 28 day treatment than after 1 and 4 day treatments. Zonisamide, carbamazepine and diazepam also increased mRNA, though differences in levels between 1, 4 and 28 day treatments were not significant. These results suggest that psychotropics modulate the gene expression of type-II nitric oxide synthase in the brain. |
| doi_str_mv | 10.1016/S0304-3940(02)01035-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72682037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304394002010352</els_id><sourcerecordid>72682037</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-1b7b238661870e0bcb622d3920a0bdd42a6e52e6ed0c2d367e615be2304e50a03</originalsourceid><addsrcrecordid>eNqFkE9v1DAQxS0EokvhI4B8AVGJwHiSOLsntKoorFSBxJ-z5diz1CjrBNupGj49zm5Ej5zs8fvN88xj7LmAtwKEfPcNSqiKclPBa8ALEFDWBT5gK7FusGg2DT5kq3_IGXsS4y8AqEVdPWZnAivclGu5Yn-2PrkhTuamT8684TqXloZAMebrXN-5vpsWzR510_vbsZt1bsP4M3Ln7WiIp2kgvttx71Jwhvd32YnHyacbHYkfvn7eZpIHnXgbtPNP2aO97iI9W85z9uPqw_fLT8X1l4-7y-11YcoGUyHapsU8q8ybAUFrWoloyw2ChtbaCrWkGkmSBZPfZUNS1C1h3p3qzJTn7NXJdwj975FiUgcXDXWd9tSPUTUo1whlk8H6BJrQxxhor4bgDjpMSoCaQ1fH0NWcqAJUx9AV5r4XywdjeyB737WknIGXC6Cj0d0-aG9cvOcqyGg1G70_cZTjuHUUVDSOvCHrApmkbO_-M8pfcI2fMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72682037</pqid></control><display><type>article</type><title>Antipsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Suzuki, Eiji ; Nakaki, Toshio ; Shintani, Futoshi ; Kanba, Shigenobu ; Miyaoka, Hitoshi</creator><creatorcontrib>Suzuki, Eiji ; Nakaki, Toshio ; Shintani, Futoshi ; Kanba, Shigenobu ; Miyaoka, Hitoshi</creatorcontrib><description>Nitric oxide synthase inhibitors have been regarded as potentially beneficial for psychiatric disorders such as depression and schizophrenia, though little is known about how nitric oxide synthases are affected by psychotropic drugs in the brain. Using reverse transcription-polymerase chain reaction analysis, we investigated the effects of short- and long-term oral treatments with several psychotropics on type II nitric oxide synthase gene expression in the rat brain. With maprotiline and fluvoxamine, enzyme mRNA levels were higher after a 28 day treatment than after 1 and 4 day treatments. Zonisamide, carbamazepine and diazepam also increased mRNA, though differences in levels between 1, 4 and 28 day treatments were not significant. These results suggest that psychotropics modulate the gene expression of type-II nitric oxide synthase in the brain.</description><identifier>ISSN: 0304-3940</identifier><identifier>EISSN: 1872-7972</identifier><identifier>DOI: 10.1016/S0304-3940(02)01035-2</identifier><identifier>PMID: 12429386</identifier><identifier>CODEN: NELED5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Animals ; Anticonvulsant ; Anticonvulsants - pharmacology ; Antidepressant ; Antidepressive Agents - pharmacology ; Antipsychotic ; Antipsychotic Agents - pharmacology ; Anxiolytic ; Biological and medical sciences ; Brain ; Brain - cytology ; Brain - drug effects ; Brain - enzymology ; Brain - metabolism ; Carbamazepine - pharmacology ; Chlorpromazine - pharmacology ; Diazepam - pharmacology ; Fluvoxamine - pharmacology ; Gene Expression - drug effects ; Haloperidol - pharmacology ; Isoxazoles - pharmacology ; Lithium - pharmacology ; Male ; Maprotiline - pharmacology ; Medical sciences ; Miscellaneous ; Neuropharmacology ; Nitric Oxide Synthase - biosynthesis ; Nitric Oxide Synthase - genetics ; Nitric Oxide Synthase Type II ; Pharmacology. Drug treatments ; Rats ; Rats, Sprague-Dawley ; Reverse Transcriptase Polymerase Chain Reaction - methods ; Reverse transcription-polymerase chain reaction ; RNA, Messenger - biosynthesis ; RNA, Messenger - drug effects ; Time Factors ; Type-II nitric oxide synthase ; Zonisamide</subject><ispartof>Neuroscience letters, 2002-11, Vol.333 (3), p.217-219</ispartof><rights>2002 Elsevier Science Ireland Ltd</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2002 Elsevier Science Ireland Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-1b7b238661870e0bcb622d3920a0bdd42a6e52e6ed0c2d367e615be2304e50a03</citedby><cites>FETCH-LOGICAL-c372t-1b7b238661870e0bcb622d3920a0bdd42a6e52e6ed0c2d367e615be2304e50a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304394002010352$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14012442$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12429386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suzuki, Eiji</creatorcontrib><creatorcontrib>Nakaki, Toshio</creatorcontrib><creatorcontrib>Shintani, Futoshi</creatorcontrib><creatorcontrib>Kanba, Shigenobu</creatorcontrib><creatorcontrib>Miyaoka, Hitoshi</creatorcontrib><title>Antipsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain</title><title>Neuroscience letters</title><addtitle>Neurosci Lett</addtitle><description>Nitric oxide synthase inhibitors have been regarded as potentially beneficial for psychiatric disorders such as depression and schizophrenia, though little is known about how nitric oxide synthases are affected by psychotropic drugs in the brain. Using reverse transcription-polymerase chain reaction analysis, we investigated the effects of short- and long-term oral treatments with several psychotropics on type II nitric oxide synthase gene expression in the rat brain. With maprotiline and fluvoxamine, enzyme mRNA levels were higher after a 28 day treatment than after 1 and 4 day treatments. Zonisamide, carbamazepine and diazepam also increased mRNA, though differences in levels between 1, 4 and 28 day treatments were not significant. These results suggest that psychotropics modulate the gene expression of type-II nitric oxide synthase in the brain.</description><subject>Animals</subject><subject>Anticonvulsant</subject><subject>Anticonvulsants - pharmacology</subject><subject>Antidepressant</subject><subject>Antidepressive Agents - pharmacology</subject><subject>Antipsychotic</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Anxiolytic</subject><subject>Biological and medical sciences</subject><subject>Brain</subject><subject>Brain - cytology</subject><subject>Brain - drug effects</subject><subject>Brain - enzymology</subject><subject>Brain - metabolism</subject><subject>Carbamazepine - pharmacology</subject><subject>Chlorpromazine - pharmacology</subject><subject>Diazepam - pharmacology</subject><subject>Fluvoxamine - pharmacology</subject><subject>Gene Expression - drug effects</subject><subject>Haloperidol - pharmacology</subject><subject>Isoxazoles - pharmacology</subject><subject>Lithium - pharmacology</subject><subject>Male</subject><subject>Maprotiline - pharmacology</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Neuropharmacology</subject><subject>Nitric Oxide Synthase - biosynthesis</subject><subject>Nitric Oxide Synthase - genetics</subject><subject>Nitric Oxide Synthase Type II</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Reverse Transcriptase Polymerase Chain Reaction - methods</subject><subject>Reverse transcription-polymerase chain reaction</subject><subject>RNA, Messenger - biosynthesis</subject><subject>RNA, Messenger - drug effects</subject><subject>Time Factors</subject><subject>Type-II nitric oxide synthase</subject><subject>Zonisamide</subject><issn>0304-3940</issn><issn>1872-7972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9v1DAQxS0EokvhI4B8AVGJwHiSOLsntKoorFSBxJ-z5diz1CjrBNupGj49zm5Ej5zs8fvN88xj7LmAtwKEfPcNSqiKclPBa8ALEFDWBT5gK7FusGg2DT5kq3_IGXsS4y8AqEVdPWZnAivclGu5Yn-2PrkhTuamT8684TqXloZAMebrXN-5vpsWzR510_vbsZt1bsP4M3Ln7WiIp2kgvttx71Jwhvd32YnHyacbHYkfvn7eZpIHnXgbtPNP2aO97iI9W85z9uPqw_fLT8X1l4-7y-11YcoGUyHapsU8q8ybAUFrWoloyw2ChtbaCrWkGkmSBZPfZUNS1C1h3p3qzJTn7NXJdwj975FiUgcXDXWd9tSPUTUo1whlk8H6BJrQxxhor4bgDjpMSoCaQ1fH0NWcqAJUx9AV5r4XywdjeyB737WknIGXC6Cj0d0-aG9cvOcqyGg1G70_cZTjuHUUVDSOvCHrApmkbO_-M8pfcI2fMg</recordid><startdate>20021129</startdate><enddate>20021129</enddate><creator>Suzuki, Eiji</creator><creator>Nakaki, Toshio</creator><creator>Shintani, Futoshi</creator><creator>Kanba, Shigenobu</creator><creator>Miyaoka, Hitoshi</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20021129</creationdate><title>Antipsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain</title><author>Suzuki, Eiji ; Nakaki, Toshio ; Shintani, Futoshi ; Kanba, Shigenobu ; Miyaoka, Hitoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-1b7b238661870e0bcb622d3920a0bdd42a6e52e6ed0c2d367e615be2304e50a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Animals</topic><topic>Anticonvulsant</topic><topic>Anticonvulsants - pharmacology</topic><topic>Antidepressant</topic><topic>Antidepressive Agents - pharmacology</topic><topic>Antipsychotic</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Anxiolytic</topic><topic>Biological and medical sciences</topic><topic>Brain</topic><topic>Brain - cytology</topic><topic>Brain - drug effects</topic><topic>Brain - enzymology</topic><topic>Brain - metabolism</topic><topic>Carbamazepine - pharmacology</topic><topic>Chlorpromazine - pharmacology</topic><topic>Diazepam - pharmacology</topic><topic>Fluvoxamine - pharmacology</topic><topic>Gene Expression - drug effects</topic><topic>Haloperidol - pharmacology</topic><topic>Isoxazoles - pharmacology</topic><topic>Lithium - pharmacology</topic><topic>Male</topic><topic>Maprotiline - pharmacology</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Neuropharmacology</topic><topic>Nitric Oxide Synthase - biosynthesis</topic><topic>Nitric Oxide Synthase - genetics</topic><topic>Nitric Oxide Synthase Type II</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Reverse Transcriptase Polymerase Chain Reaction - methods</topic><topic>Reverse transcription-polymerase chain reaction</topic><topic>RNA, Messenger - biosynthesis</topic><topic>RNA, Messenger - drug effects</topic><topic>Time Factors</topic><topic>Type-II nitric oxide synthase</topic><topic>Zonisamide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suzuki, Eiji</creatorcontrib><creatorcontrib>Nakaki, Toshio</creatorcontrib><creatorcontrib>Shintani, Futoshi</creatorcontrib><creatorcontrib>Kanba, Shigenobu</creatorcontrib><creatorcontrib>Miyaoka, Hitoshi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neuroscience letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suzuki, Eiji</au><au>Nakaki, Toshio</au><au>Shintani, Futoshi</au><au>Kanba, Shigenobu</au><au>Miyaoka, Hitoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antipsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain</atitle><jtitle>Neuroscience letters</jtitle><addtitle>Neurosci Lett</addtitle><date>2002-11-29</date><risdate>2002</risdate><volume>333</volume><issue>3</issue><spage>217</spage><epage>219</epage><pages>217-219</pages><issn>0304-3940</issn><eissn>1872-7972</eissn><coden>NELED5</coden><abstract>Nitric oxide synthase inhibitors have been regarded as potentially beneficial for psychiatric disorders such as depression and schizophrenia, though little is known about how nitric oxide synthases are affected by psychotropic drugs in the brain. Using reverse transcription-polymerase chain reaction analysis, we investigated the effects of short- and long-term oral treatments with several psychotropics on type II nitric oxide synthase gene expression in the rat brain. With maprotiline and fluvoxamine, enzyme mRNA levels were higher after a 28 day treatment than after 1 and 4 day treatments. Zonisamide, carbamazepine and diazepam also increased mRNA, though differences in levels between 1, 4 and 28 day treatments were not significant. These results suggest that psychotropics modulate the gene expression of type-II nitric oxide synthase in the brain.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>12429386</pmid><doi>10.1016/S0304-3940(02)01035-2</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3940 |
| ispartof | Neuroscience letters, 2002-11, Vol.333 (3), p.217-219 |
| issn | 0304-3940 1872-7972 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72682037 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Anticonvulsant Anticonvulsants - pharmacology Antidepressant Antidepressive Agents - pharmacology Antipsychotic Antipsychotic Agents - pharmacology Anxiolytic Biological and medical sciences Brain Brain - cytology Brain - drug effects Brain - enzymology Brain - metabolism Carbamazepine - pharmacology Chlorpromazine - pharmacology Diazepam - pharmacology Fluvoxamine - pharmacology Gene Expression - drug effects Haloperidol - pharmacology Isoxazoles - pharmacology Lithium - pharmacology Male Maprotiline - pharmacology Medical sciences Miscellaneous Neuropharmacology Nitric Oxide Synthase - biosynthesis Nitric Oxide Synthase - genetics Nitric Oxide Synthase Type II Pharmacology. Drug treatments Rats Rats, Sprague-Dawley Reverse Transcriptase Polymerase Chain Reaction - methods Reverse transcription-polymerase chain reaction RNA, Messenger - biosynthesis RNA, Messenger - drug effects Time Factors Type-II nitric oxide synthase Zonisamide |
| title | Antipsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T01%3A43%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antipsychotic,%20antidepressant,%20anxiolytic,%20and%20anticonvulsant%20drugs%20induce%20type%20II%20nitric%20oxide%20synthase%20mRNA%20in%20rat%20brain&rft.jtitle=Neuroscience%20letters&rft.au=Suzuki,%20Eiji&rft.date=2002-11-29&rft.volume=333&rft.issue=3&rft.spage=217&rft.epage=219&rft.pages=217-219&rft.issn=0304-3940&rft.eissn=1872-7972&rft.coden=NELED5&rft_id=info:doi/10.1016/S0304-3940(02)01035-2&rft_dat=%3Cproquest_cross%3E72682037%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72682037&rft_id=info:pmid/12429386&rft_els_id=S0304394002010352&rfr_iscdi=true |